Table 1 Patient demographics and baseline characteristics

Median Age in Years (range)

59 (44, 75)

60 (37, 79)

52 (34, 57)

58 (34, 79)

Gender

 Male

10 (66.7%)

13 (81.3%)

2 (66.7%)

25 (73.5%)

 Female

5 (33.3%)

3 (18.8%)

1 (33.3%)

9 (26.5%)

Pathological Type

 AITL

7 (46.7%)

8 (50.0%)

0

15 (44.1%)

 PTCL-NOS

5 (33.3%)

5 (31.3%)

1 (33.3%)

11 (32.4%)

 ALK-ALCL

2 (13.3%)

0

1 (33.3%)

3 (8.8%)

 NKTCL

0

2 (12.5%)

0

2 (5.9%)

 TFH-NOS

1 (6.7%)

1 (6.3%)

0

2 (5.9%)

 SKIN-PTCL

0

0

1 (33.3%)

1 (2.9%)

ECOG performance status

 0

2 (13.3%)

5 (31.3%)

2 (66.7%)

9 (26.5%)

 1

13 (86.7%)

11 (68.8%)

1 (33.3%)

25 (73.5%)

Ann-Arbor Stage

 I

0

0

0

0

 II

0

2 (12.5%)

0

2 (5.9%)

 III

6 (40.0%)

4 (25.0%)

1 (33.3%)

11 (32.3%)

 IV

9 (60.0%)

10(62.5%)

2(66.7%)

21 (61.8%)

Autologous hematopoietic stem cell transplantation

1 (6.7%)

0

0

1 (2.9%)

Median Number of Prior Lines (range)

2 (1, 2)

2 (1, 3)

2 (2, 5)

2 (1, 5)

Previous systemic therapies

 CHOP/CHOP-like regimen

15 (100.0%)

13 (81.3%)

3 (100.0%)

31 (91.2%)

 including chidamide regimen

5 (33.3%)

6 (37.5%)

2 (66.7%)

13 (38.2%)

 including thalidomide regimen

3 (20.0%)

3 (18.8%)

0

6 (17.6%)

 including brentuximab regimen

1 (6.7%)

1 (6.3%)

0

2 (5.9%)

 including azacitidine regimen

1 (6.7%)

0

1 (33.3%)

2 (5.9%)

 including PD-1 regimen

0

2 (12.5%)

0

2 (5.9%)

 Other drugs^#

2 (13.3%)

2 (13.3%)

0

4 (11.7%)

Refractory to last regimen

10(66.7%)

14(87.5%)

2(66.7%)

26(76.5%)